Monopar Therapeutics Inc [MNPR] stock is trading at $28.54, down -6.36%. An important factor to consider is whether the stock is rising or falling in short-term value. The MNPR shares have gain 12.58% over the last week, with a monthly amount glided 6.89%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Monopar Therapeutics Inc [NASDAQ: MNPR] stock has seen the most recent analyst activity on January 10, 2025, when Piper Sandler initiated its Overweight rating and assigned the stock a price target of $72. Previously, Rodman & Renshaw started tracking the stock with Buy rating on October 11, 2024, and set its price target to $50. On January 28, 2021, ROTH Capital initiated with a Buy rating and assigned a price target of $49 on the stock.
Monopar Therapeutics Inc [MNPR] stock has fluctuated between $1.54 and $38.50 over the past year. Currently, Wall Street analysts expect the stock to reach $29.5 within the next 12 months. Monopar Therapeutics Inc [NASDAQ: MNPR] shares were valued at $28.54 at the most recent close of the market. An investor can expect a potential return of 3.36% based on the average MNPR price forecast.
Analyzing the MNPR fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -215.74, Equity is -217.32 and Total Capital is -1.41.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 26.15 points at the first support level, and at 23.77 for the second support level. However, for the 1st resistance point, the stock is sitting at 31.44, and for the 2nd resistance point, it is at 34.34.
Ratios To Look Out For
For context, Monopar Therapeutics Inc’s Current Ratio is 5.41. On the other hand, the Quick Ratio is 5.41, and the Cash Ratio is 5.36.
Transactions by insiders
Recent insider trading involved Radhakrishnan Karthik, Chief Financial Officer, that happened on Oct 28 ’24 when 1550.0 shares were purchased. Chief Operating Officer, Cittadine Andrew completed a deal on Jun 20 ’24 to buy 20508.0 shares. Meanwhile, Chief Operating Officer Cittadine Andrew bought 12000.0 shares on Jun 18 ’24.
